Malvern-based biopharmaceutical company Ocugen completed its previously announced $100 million private stock sale. Almost all the headlines about Ocugen in the past year have been about the companys COVID-19 vaccine candidate. But any success they find will be without me as a shareholder. UPDATE 1-Soccer-Traore on target as Wolves stun wasteful Spurs, Peruvian communities to resume blockade of crucial "mining corridor", One student loan forgiveness effort 'hasnt gotten the attention it deserves': expert, RPT-Death toll in strike on Ukraine's Zaporizhzhia rises to 11 - officials, Soccer-Traore on target as Wolves stun wasteful Spurs. However, I wont be around to find out. There's a pretty good case to be made that other stocks offer even better prospects for returns with lower risk than Ocugen does. With this, the newly formed Ocugen initiated a 60:1 reverse stock split. If Ocugen goes up, you can still profit. While anything is possible, I would not anticipate a miracle here. Here are three prudent steps to take. You canfollow Will on Twitterat @HealyWriting. Literally, zero. The Nasdaq has been even more impressive, rallying 67.7% in the same time frame and hitting new all-time highs in the process. For example, after the FDA revised its guidelines for the EUA process for COVID-19 vaccines, Ocugen's CEO stated, "Since we have been in discussions with the FDA since late last year, we do not believe that the FDA's recently revised guidance regarding EUAs raises any concerns about our ability to submit the EUA for Covaxin as planned." CEO Shankar Musunuri stated that he was "pleased to say" that Ocugen was in discussions with the FDA about the data it had submitted for the pediatric EUA. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. The combined company has an agreement to sell the rights to NeoCart to privately held Medavate, leaving it reliant on Ocugens pipeline. It has no treatments to offer the market. If they have solid financials, but their trials continually fail, they will likely not succeed. Moreover, Histogenics existed to treat orthopedic conditions, while Ocugen focused on rare eye diseases. The FDA told the company in June 2021 that it should instead follow the standard path to full approval of the vaccine in adults. Do Not Sell My Personal Information (CA Residents Only). How long might it take for Ocugen to win full FDA approval for Covaxin? But there is no question some big-name stocks performed better than others along the way. Even though Ocugen did raise $25 million in a private placement, the story behind OCU300 clearly was not enough to support an initial public offering on its own. Ocugen isnt a promotional, fly-by-night penny stock. Since its merger, Ocugen stock has continued the decline that occurred under the company that it took over, Histogenics. The sale of NeoCart, which still is pending, can bring in another $8 million, based on the current agreement. 1125 N. Charles St, Baltimore, MD 21201. 1125 N. Charles St, Baltimore, MD 21201. Do Not Sell My Personal Information (CA Residents Only). Plus500. Conditions have only become worse since that time. This decision. As with many biotech stocks, the most likely outcome is for the company to fail, and for shareholders to wind up with zero. Stock Price Forecast The 6 analysts offering 12-month price forecasts for Ocugen Inc have a median target of 4.75, with a high estimate of 8.00 and a low estimate of 3.00. The reverse merger that brought Ocugen to the public markets led to huge losses but some investors are buying the dip. However, even from this limited vantage point, OCGN appears destined to fail. CanSinoBio will receive some of the profits, but Ocugen still would skyrocket with FDA approval and ensuing revenue and there are more products in the pipeline. Theres even room for more lines. A $30 million market capitalization doesnt mean Ocugen has no chance. Source: Chart courtesy of StockCharts.com. Cost basis and return based on previous market day close. According to the prospectus, the combined company posted an operating loss of roughly $30 million in 2018. Ocugen In 2021, Beyond: Optimism about Covaxin coupled with massive short squeezes in a handful of popular social media stocks sent Ocugen shares skyrocketing up to as high as $18.77 in February 2021. The company stated that it will pursue a path to file for full FDA approval of Covaxin. Weitere Informationen ber die Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie. Instead of buying a piece of the S&P 500 or Nasdaq or even better, a common sense mega-holding like Apple (NASDAQ:AAPL) or Amazon investors in OCGN stock took on a high-risk investment and for months saw negative returns. ET by MarketWatch Automation Ocugen Inc. stock falls Tuesday, underperforms market Feb. 21, 2023 at 5:14. Its all about choice. The Ocugen deal is a way to salvage some limited value. This can prove to be a costly lesson to learn. Please check your download folder. Conditions only seem to get worse for Ocugen (NASDAQ:OCGN). Ocugen shares jumped to $3.50 on massive volume in December when the Covaxin partnership was announced. For now, though, what happens in India stays in India. The stock dropped as low as 26 cents during the height of the pandemic fears in March 2020. Please check your download folder. It means that raising capital will be more difficult going forward. Ocugen announced in late Decemberit had signed a letter of intent to co-develop COVID-19 vaccine candidate Covaxin along with Indian pharmaceutical company Bharat Biotech. Ocugen Inc Stock - OCGN Share Price Today, News and Discussion 0.90% SPY 0.59% QQQ 0.60% TSLA 6.12% SI 60.35% CRM 11.51% RIVN 0.32% ARKK 0.96% RLY.X 56.44% PLUG 6.72% V 0.22% CDIO 13.87% RETA 5.92% More Advertisement 3rd Party Ad. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The agreement stipulates Ocugen will hold the vaccines U.S. rights, and the remaining details are expected to be finalized over the coming weeks. Lorem ipsum dolor sit amet, consectetur adipiscing elit. The odds of Ocugen stock winding up at zero are material. 2023 InvestorPlace Media, LLC. The post There Are So Many Stocks to Buy Ocugen Isnt One of Them appeared first on InvestorPlace. Maybe it pans out for Ocugen and I wish the team (and its investors) the best of luck. Keith Speights owns shares of Pfizer. It's easy to become such a huge fan of a stock that you lose objectivity about its prospects. If you already owned Ocugen stock before the company's disappointing news, you have several alternatives. Its worth emphasizing: Ocugen stock is a play with enormous risk. Investors who have owned stocks in the last year have generally experienced some big gains. Do not expect this to become the biotech who made good like Biogen (NASDAQ:BIIB). Other than an emphasis on cell therapies, the companies had almost nothing in common. In other words, it means that even by biotech standards OCGN stock is an enormously risky play. The chances of anything more are small but the rewards could be huge. Will Be Even Bigger Than Your Wildest Expectation, 7 Over-$100 Stocks That Are Worth Every Penny, Louis Navellier and the InvestorPlace Research Staff, 5 Penny Cryptos With the Most Potential for Growth. OCU300 already has received an orphan drug designation from the U.S. Food & Drug Administration for oGVHD; there is no currently approved treatment in the U.S. The Motley Fool recommends Moderna Inc. Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. This requires no immediate effort on your part. Today, the stock has a $1.6 billion market cap despite just $42,620 in 2020 revenue. The stock had gained some traction after they announced the Ocugen merger in April. Shares of Ocugen ( OCGN -3.10%) fell on Tuesday after an analyst sounded a note of caution to investors. That's right -- they think these 10 stocks are even better buys. *Average returns of all recommendations since inception. Type a symbol or company name. Written by When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. OCGN does not even appear to have an apparent reason to exist. With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell Amryt Pharma releases Q-2 how to setup copy trading labrador gold stock that show strong revenue growth as The first split for NKE took place on October 08, Below, we'll pit these two dominant consumer-discretionary giants against each other, with an eye toward long-term . Copyright 2023 InvestorPlace Media, LLC. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. Ocugen ( NASDAQ: OCGN) has been one of the more polarizing story stocks of 2021. The Motley Fool->. In fact, $1,000 in Ocugen stock bought on Aug. 9, 2020, would be worth about $15,100 today. With $3.2 million in cash vs. current liabilities of $3.3 million, Ocugen likely has enough cash on hand to cover its short-term obligations. Like Pfizer's BNT162b2 and Moderna's mRNA-1273, it requires two doses. However, sometimes the optimism isn't justified. The all-time high Ocugen stock closing price was, The average Ocugen stock price for the last 52 weeks is. It took Moderna roughly 10 months from the initiation of the late-stage study for its COVID-19 vaccine to the point where the company filed for full FDA approval. Our 3 Top Picks. Theres an opportunity here. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. The equity has experienced a continual decline for years. It means that institutional investors focused on the sector largely have passed on the pipeline.

Onenote Stickers Missing, The Gone Home Incident August 13, 2010, How To Mute Yourself On Discord Iphone, Enhanced Http Sccm, Articles O